Monday, May 08, 2017 3:24:52 PM
Reformulated SequestOx™ will be the first IR ADF opiod to receive ORAL, Nasal and IV ADF labeling
Inspirion's RoxyBond lost big by not getting oral AD labeling
SequestOx will make their product obsolete by years end.
Reformulated SequestOx™ with lowered fed Tmax is now the SAFEST Immediate Release opiod in the world, and the only one using a Pharmalogical Approach to abuse deterrence.
To date there have been no adverse events with Elites SequestOx™,
This is what Congress, President, FDA and the Public are looking for.
Perfect storm for Elite, right place-right time
SequestOx™ Elite's market disruptive ADF labeled Immediate Release opiod
can not be abused by:
NASAL:
Insuffalation/snorting all particle sizes
IV:
injecting/IV/poor syringe ability
Smoking:
ORAL:
chewing
crushing/mechanical manipulation
grating
milling
sucking
splitting
breaking
grinding
use with alcohol
sandpapering
blended
melting
microwave
baking
freezing
extracting
centrifuging
bead separation
difficult to defeat with common solvents
Inspirion's RoxyBond lost big by not getting oral AD labeling
SequestOx will make their product obsolete by years end.
Reformulated SequestOx™ with lowered fed Tmax is now the SAFEST Immediate Release opiod in the world, and the only one using a Pharmalogical Approach to abuse deterrence.
To date there have been no adverse events with Elites SequestOx™,
This is what Congress, President, FDA and the Public are looking for.
Perfect storm for Elite, right place-right time
SequestOx™ Elite's market disruptive ADF labeled Immediate Release opiod
can not be abused by:
NASAL:
Insuffalation/snorting all particle sizes
IV:
injecting/IV/poor syringe ability
Smoking:
ORAL:
chewing
crushing/mechanical manipulation
grating
milling
sucking
splitting
breaking
grinding
use with alcohol
sandpapering
blended
melting
microwave
baking
freezing
extracting
centrifuging
bead separation
difficult to defeat with common solvents
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
